Compare RBKB & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBKB | ELDN |
|---|---|---|
| Founded | 1860 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.3M | 208.6M |
| IPO Year | 2018 | 2014 |
| Metric | RBKB | ELDN |
|---|---|---|
| Price | $16.01 | $2.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 16.3K | ★ 900.4K |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.27 |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $3,002,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.51 | ★ N/A |
| Revenue Growth | ★ 4.24 | N/A |
| 52 Week Low | $9.31 | $1.35 |
| 52 Week High | $16.50 | $4.60 |
| Indicator | RBKB | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 64.09 | 58.67 |
| Support Level | $11.38 | $2.48 |
| Resistance Level | $16.32 | $2.77 |
| Average True Range (ATR) | 0.52 | 0.21 |
| MACD | -0.13 | 0.02 |
| Stochastic Oscillator | 65.76 | 54.23 |
Rhinebeck Bancorp Inc is the holding company for Rhinebeck Bank which provides a full range of banking and financial services to consumer and commercial customers. Financial services, including investment advisory and financial product sales, are offered through a division of the Bank doing business as Rhinebeck Asset Management (RAM). The Bank's primary business activity is accepting deposits from the general public and using those funds to originate indirect automobile loans (automobile loans referred by automobile dealerships), commercial real estate loans (which include multi-family real estate loans and commercial construction loans), commercial business loans and one-to four-family residential real estate loans, and to purchase investment securities.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.